Literature DB >> 7853017

Prevention of HIV coat protein (gp120) toxicity in cortical cell cultures by riluzole.

P Sindou1, P Couratier, F Esclaire, C Yardin, A Bousseau, J Hugon.   

Abstract

Neurological complications observed in HIV-infected patients are very frequent. Neocortical lesions include reduced neuronal density due to neuronal degeneration. The HIV envelope protein gp120 has potent neurotoxic properties in cell cultures blocked either by NMDA antagonists or calcium channel antagonists. Moreover, human monocytoid cell lines infected by HIV release endogenous toxic factors with comparable cellular actions. We have analysed the effects of riluzole, a compound reducing the excitatory amino acid release on gp120-induced neurotoxicity in primary neuronal cultures. Riluzole, which blocks the release of glutamate and aspartate from nerve terminals, prevents (10(-7) M) the neuronal degeneration produced by 20 pM of gp120 in cortical cell cultures. This result could suggest that toxic factors produced by activated macrophages might increase glutamate release, and that this may be prevented by riluzole.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7853017     DOI: 10.1016/0022-510x(94)90262-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity.

Authors:  Ajit G Thomas; Amos Bodner; Ghanashyam Ghadge; Raymond P Roos; Barbara S Slusher
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

2.  The gp120 protein is a second determinant of decreased neurovirulence of Indian HIV-1C isolates compared to southern African HIV-1C isolates.

Authors:  Vasudev R Rao; Ujjwal Neogi; Eliseo Eugenin; Vinayaka R Prasad
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

Review 3.  Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders.

Authors:  Michelle C Potter; Mariana Figuera-Losada; Camilo Rojas; Barbara S Slusher
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-04       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.